Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Against Misuse Of Thermal Imaging Systems

Executive Summary

The devices may be less accurate when used to screen multiple people at once, the US agency says.

You may also be interested in...



COVID-19: Telethermographic Systems Not OK’d By FDA Can Be Used For Medical Purposes

The temperature-detection devices are the latest target for enforcement policy guidance by the US agency, which says it will look the other way when it comes to regulatory compliance by makers of non-FDA-approved telethermographic systems.

FDA’s 5 Steps To A Successful ASCA Pilot Submission

Sponsors participating in the US FDA’s Accreditation Scheme for Conformity Assessment pilot program should work closely with the lab and be prepared for a few extra steps in putting a submission together, agency staff say.

Biden Budget Proposal Includes $905M For Medical Supply Stockpile

The $1.5tn proposal includes limited information about the US FDA, but makes pandemic recovery a clear priority.

Topics

UsernamePublicRestriction

Register

MT143608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel